Keywords: HIV/AIDS, drug resistance, Europe, Market

European demand for therapies to treat drug resistant HIV strains is increasing

Article | 29 September 2009

The HIV/AIDS market in Europe faces a number of hurdles in the form of late diagnosis and low awareness levels. However, the market is projected to exhibit strong growth due to the introduction of novel drug classes and increasing efforts to achieve high diagnosis rates. New analysis from Frost & Sullivan), European HIV/AIDS Therapeutics Markets, finds that the markets earned revenues of $3.88 billion in 2008 and estimates this to reach $6.79 billion in 2015.

"Market growth will be spurred by the new drug classes and combination therapies introduced recently," notes Sylvia M. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in